Editing Freehand

==Summary==

FreeHand is a robotic surgical camera controller that provides rock-steady images and precise control saving time and improving outcomes. With regulatory approval in the EU, US and Japan, Freehand is fundraising to support sales growth.

* The market for surgical robotics is expected to reach $91.5B by 2025
* FreeHand has regulatory clearance for sale in the EU, US and Japan
* Surgeons have successfully used FreeHand in >15,000 procedures
* >12M applicable procedures happen every year

==Idea==

<html>
<iframe width="560" height="315" src="https://player.vimeo.com/video/493701802?h=84c1ec102d" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture" allowfullscreen></iframe>
</html>

Over 15 million keyhole surgeries are performed annually. Common procedures include appendectomies, gall bladder removal, hernia repair and cancer treatment. Most of these require an additional clinician in theatre to manually hold the camera the surgeon uses to see the operating field.

Anyone who has seen a shaky cell-phone video knows that holding objects steady for long periods of time is not something humans do well. Hand-held surgical cameras produce sub-optimal images with shake, drift and rotation. The patented FreeHand robotic camera controller provides a clear, rock steady image giving the surgeon full and precise control.

Studies show that FreeHand can REDUCE:

* Operating time by up to 20%

* Post-operative recovery time and complications

* Surgical training time

* Theatre head-count

Surgical robotics is one of the fastest-growing segments in MedTech, projected to reach $91.5B by 2025. FreeHand provides hospitals with an affordable, easy-to-use platform to realise the benefits of robotic assistance in operating rooms.

With the hiring of an experienced VP of Sales in May of 2019 and the launch of Freehand Panorama, the company now has hospitals and distributors signed up in the UK, Spain, Netherlands and Italy.

This investment will fund expansion of distributor base in Europe, Asia and Latin America, targeting over 12 million procedures annually.

==Team==

'''Christopher Jones, Chairman'''

Over 30 years experience in Fortune 500 and start-up MedTech companies. Chair of Mologic and Elasmogen. Former CEO of GlySure Medical, CEO Tensys Medical and VP Marketing for $700M Nellcor Division of Tyco Healthcare.

'''Jeremy Russell, CEO'''

Former Technical Director of Biocompatibles and R&D Director at Smiths Medical where he brought over 70 new MedTech products to market. Deep experience in medical product development, regulatory, quality, manufacturing and operations.

'''Arnaud Laylle, VP Sales & Marketing'''

Over 20 years experience in Sales Management and launch of new surgical devices. Former VP EMEA SpineArt, Director of International Sales Medicrea, Manager EMEA & Latin America Spine Next. Extensive knowledge of distributor selection, development and management.

'''Maxine Oxford, Non Executive Director'''

Over 15 years of medical device sales and management experience. Currently UK Sales and Marketing Director for Oticon Medical. Previous roles include Sales Management at Coloplast, and Corin UK. Maxine brings extensive experience selling novel, first-in class medical products.

'''Ben Reid, Non Executive Director'''

CEO of Aspremont, which has partnered with FreeHand to provide experienced strategic, commercial and financial support. Ben brings a history of creating successful business models for early-stage, disruptive businesses
[[Category:Thesis]]
[[Category:Equities]]

__INDEX__